Posted by Michael Wonder on 08 Feb 2023
Regorafenib monohydrate for patients with previously treated metastatic colorectal cancer
8 February 2023 - Regorafenib monohydrate is recommended as an option for the treatment of adults with metastatic colorectal cancer who have had previous treatment (including fluoropyrimidine-based chemotherapy, anti‑VEGF therapy and anti‑EGFR therapy) or when these treatments are unsuitable.
Regorafenib monohydrate is only recommended if Bayer provides it according to the commercial arrangement.
